The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The phase II MagnetisMM-3 study of Elrexfio (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Fenghuang “Frank” Zhan invested in inaugural Bart Barlogie Chair for Myeloma Research

Zhan, seated, with Steven Webber (left), dean of the College of Medicine and executive vice chancellor at UAMS, and UAMS chancellor Cam Patterson (right).The University of Arkansas for Medical Sciences College of Medicine invested Fenghuang “Frank” Zhan, a tenured professor of medicine and the research director of the UAMS Winthrop P. Rockefeller Cancer Institute’s Myeloma Center, in the Bart Barlogie Chair for Myeloma Research during a March 13 ceremony. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account